Monte Rosa Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 13, 2025. During the meeting, stockholders voted on two key proposals. The first proposal was to elect Christine Siu, Kimberly Blackwell, and Jan Skvarka as Class I directors of the company, which was approved. The second proposal was to ratify the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.